A method for the simultaneous measurement of the new anthracycline derivative 4′ -deoxydoxorubicin and its metabolites by reversed phase liquid chromatography

Yei Mei Peng, David S Alberts, Sydney E. Salmon, Thomas P Davis

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The anthracycline analog 4′-deoxydoxorubicin (4′ -deoxyDX) is a clinically promising antineoplastic agent due to its high potency, broad spectrum of activity, and decreased cardiotoxicity relative to DX. To assess its physicochemical properties and disposition kinetics, we have developed a rapid, sensitive, and precise HPLC assay for the simultaneous analysis of 4′ -deoxyDX and its potential metabolites in biological samples. The assay has a detection limit of 5 ng/ml with an average recovery of 95 ± 5%. Precision of the assay is less than 7%. Using this assay we have measured the concentrations of 4′-deoxyDX in patient plasma and urine after an intravenous injection of 4′-deoxyDX. A major metabolite, which co-eluted chromatographically with 4′-deoxydoxorubicinol, was observed in both plasma and urine.

Original languageEnglish (US)
Pages (from-to)277-280
Number of pages4
JournalInvestigational New Drugs
Volume2
Issue number3
DOIs
StatePublished - Sep 1984

Fingerprint

Anthracyclines
Reverse-Phase Chromatography
Urine
Intravenous Injections
Antineoplastic Agents
Limit of Detection
High Pressure Liquid Chromatography
esorubicin
Cardiotoxicity
4'-deoxydoxorubicinol

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

@article{db080aaf3f6342cfbed7dfd1b4b1d4a5,
title = "A method for the simultaneous measurement of the new anthracycline derivative 4′ -deoxydoxorubicin and its metabolites by reversed phase liquid chromatography",
abstract = "The anthracycline analog 4′-deoxydoxorubicin (4′ -deoxyDX) is a clinically promising antineoplastic agent due to its high potency, broad spectrum of activity, and decreased cardiotoxicity relative to DX. To assess its physicochemical properties and disposition kinetics, we have developed a rapid, sensitive, and precise HPLC assay for the simultaneous analysis of 4′ -deoxyDX and its potential metabolites in biological samples. The assay has a detection limit of 5 ng/ml with an average recovery of 95 ± 5{\%}. Precision of the assay is less than 7{\%}. Using this assay we have measured the concentrations of 4′-deoxyDX in patient plasma and urine after an intravenous injection of 4′-deoxyDX. A major metabolite, which co-eluted chromatographically with 4′-deoxydoxorubicinol, was observed in both plasma and urine.",
author = "Peng, {Yei Mei} and Alberts, {David S} and Salmon, {Sydney E.} and Davis, {Thomas P}",
year = "1984",
month = "9",
doi = "10.1007/BF00175377",
language = "English (US)",
volume = "2",
pages = "277--280",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - A method for the simultaneous measurement of the new anthracycline derivative 4′ -deoxydoxorubicin and its metabolites by reversed phase liquid chromatography

AU - Peng, Yei Mei

AU - Alberts, David S

AU - Salmon, Sydney E.

AU - Davis, Thomas P

PY - 1984/9

Y1 - 1984/9

N2 - The anthracycline analog 4′-deoxydoxorubicin (4′ -deoxyDX) is a clinically promising antineoplastic agent due to its high potency, broad spectrum of activity, and decreased cardiotoxicity relative to DX. To assess its physicochemical properties and disposition kinetics, we have developed a rapid, sensitive, and precise HPLC assay for the simultaneous analysis of 4′ -deoxyDX and its potential metabolites in biological samples. The assay has a detection limit of 5 ng/ml with an average recovery of 95 ± 5%. Precision of the assay is less than 7%. Using this assay we have measured the concentrations of 4′-deoxyDX in patient plasma and urine after an intravenous injection of 4′-deoxyDX. A major metabolite, which co-eluted chromatographically with 4′-deoxydoxorubicinol, was observed in both plasma and urine.

AB - The anthracycline analog 4′-deoxydoxorubicin (4′ -deoxyDX) is a clinically promising antineoplastic agent due to its high potency, broad spectrum of activity, and decreased cardiotoxicity relative to DX. To assess its physicochemical properties and disposition kinetics, we have developed a rapid, sensitive, and precise HPLC assay for the simultaneous analysis of 4′ -deoxyDX and its potential metabolites in biological samples. The assay has a detection limit of 5 ng/ml with an average recovery of 95 ± 5%. Precision of the assay is less than 7%. Using this assay we have measured the concentrations of 4′-deoxyDX in patient plasma and urine after an intravenous injection of 4′-deoxyDX. A major metabolite, which co-eluted chromatographically with 4′-deoxydoxorubicinol, was observed in both plasma and urine.

UR - http://www.scopus.com/inward/record.url?scp=0021287010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021287010&partnerID=8YFLogxK

U2 - 10.1007/BF00175377

DO - 10.1007/BF00175377

M3 - Article

C2 - 6511234

AN - SCOPUS:0021287010

VL - 2

SP - 277

EP - 280

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 3

ER -